Bevemipretide | 2356106-71-1

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: Bevemipretide
• 英文别名: (2R)-2-amino-N-[(2S)-1-[[(1S)-5-amino-1-(3-benzyl-1,2,4-oxadiazol-5-yl)pentyl]amino]-3-(4-hydroxy-2,6-dimethylphenyl)-1-oxopropan-2-yl]-5-(diaminomethylideneamino)pentanamide
• CAS: 2356106-71-1
• 化学式: C₃₁H₄₅N₉O₄
• 分子量: 607.7
• InChiKey: XEYINAAYNXIXPY-ZNZIZOMTSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  44
• 可旋转键数：
  17
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.45
• 拓扑面积：
  234
• 氢给体数：
  7
• 氢受体数：
  9

文献信息

• [EN] MITOCHONDRIA-TARGETING PEPTIDES<br/>[FR] PEPTIDES CIBLANT LES MITOCHONDRIES
  申请人：STEALTH BIOTHERAPEUTICS CORP

  公开号：WO2019118878A1

  公开（公告）日：2019-06-20

  Disclosed are non-natural peptides useful for the treatment and prevention of ischemia-reperfusion injury (e.g., cardiac ischemia-reperfusion injury) or myocardial infarction.

  披露了用于治疗和预防缺血再灌注损伤（例如心脏缺血再灌注损伤）或心肌梗死的非天然肽。
• Compositions and Methods for the Treatment of Amyotrophic Lateral Sclerosis, Parkinson's Disease, Parkinson's Disease with Dementia, Dementia with Lewy Bodies, and Multiple System Atrophy
  申请人：Keefe Dennis

  公开号：US20210023062A1

  公开（公告）日：2021-01-28

  The present disclosure provides novel methods for treating or preventing amyotrophic lateral sclerosis (ALS), methods for delaying the onset of neurological symptoms associated with ALS, increasing survival in subjects afflicted with ALS, and attenuating the decline of muscle strength associated with ALS in a subject in need thereof. The present disclosure also provides methods for treating or preventing α-synucleinopathy or TDP-43 proteinopathy. The methods comprise administering to the subject an effective amount of a mitochondria-targeting peptidomimetic compound, such as (R)-2-amino-N—((S)-1-(((S)-5-amino-1-(3-benzyl-1,2,4-oxadiazol-5-yl)pentyl)amino)-3-(4-hydroxy-2,6-dimethylphenyl)-1-oxopropan-2-yl)-5-guanidinopentanamide, or a pharmaceutically acceptable salt, stereoisomer, tautomer, hydrate, and/or solvate thereof.

  本公开提供了治疗或预防肌萎缩侧索硬化症（ALS）的新方法，延迟与ALS相关的神经症状的发作，增加患有ALS的受试者的生存率，并减轻需要的受试者与ALS相关的肌肉力量下降。本公开还提供了治疗或预防α-突触核蛋白病或TDP-43蛋白病的方法。这些方法包括向受试者施用有效量的以线粒体为靶点的肽类似化合物，例如（R）-2-氨基-N-（（S）-1-（（S）-5-氨基-1-（3-苄基-1,2,4-噁唑-5-基）戊基）氨基）-3-（4-羟基-2,6-二甲基苯基）-1-氧代丙酰-2-基）-5-鸟氨酰基戊酰胺，或其药学上可接受的盐、立体异构体、互变异构体、水合物和/或溶剂化物。
• Compositions and methods for the treatment of amyotrophic lateral sclerosis, Parkinson's disease, Parkinson's disease with dementia, dementia with Lewy bodies, and multiple system atrophy
  申请人：Keefe Dennis

  公开号：US11273149B2

  公开（公告）日：2022-03-15

  The present disclosure provides novel methods for treating or preventing amyotrophic lateral sclerosis (ALS), methods for delaying the onset of neurological symptoms associated with ALS, increasing survival in subjects afflicted with ALS, and attenuating the decline of muscle strength associated with ALS in a subject in need thereof. The present disclosure also provides methods for treating or preventing α-synucleinopathy or TDP-43 proteinopathy. The methods comprise administering to the subject an effective amount of a mitochondria-targeting peptidomimetic compound, such as (R)-2-amino-N—((S)-1-(((S)-5-amino-1-(3-benzyl-1,2,4-oxadiazol-5-yl)pentyl)amino)-3-(4-hydroxy-2,6-dimethylphenyl)-1-oxopropan-2-yl)-5-guanidinopentanamide, or a pharmaceutically acceptable salt, stereoisomer, tautomer, hydrate, and/or solvate thereof.

  本公开内容提供了治疗或预防肌萎缩性脊髓侧索硬化症（ALS）的新方法、延缓与ALS相关的神经症状发作的方法、提高ALS患者存活率的方法，以及减轻有需要的受试者与ALS相关的肌力下降的方法。本公开还提供了治疗或预防α-突触核蛋白病或TDP-43蛋白病的方法。这些方法包括向受试者施用有效量的线粒体靶向拟肽化合物，如(R)-2-氨基-N-((S)-1-((S)-5-氨基-1-(3-苄基-1,2、4-恶二唑-5-基）戊基）氨基）-3-（4-羟基-2,6-二甲基苯基）-1-氧代丙烷-2-基）-5-胍基戊酰胺，或其药学上可接受的盐、立体异构体、同分异构体、水合物和/或溶液。
• MITOCHONDRIA-TARGETING PEPTIDES
  申请人：Stealth Biotherapeutics Corp

  公开号：EP3723783A1

  公开（公告）日：2020-10-21